Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05422105
Other study ID # PB01-MCTNSPC
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 1, 2023
Est. completion date December 31, 2024

Study information

Verified date August 2023
Source Primo Biotechnology Co., Ltd
Contact Yating Huang
Phone +886916140167
Email frankie.huang@primobt.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The diagnostic tools for detecting patients with early prostate cancer are limited due to poor diagnostic performance. The positron emission tomography (PET) combination with the diagnostic radiopharmacy is a non-invasive tool to provide the molecular imaging of the whole body and offer more comprehensive physiological information and then can raise the diagnostic performance. Prostate-specific membrane antigen (PSMA)-targeting pharmaceuticals have been regarded as the most promising diagnostic tool to diagnose patients with prostate cancer. Currently, the 18F-PSMA-1007 as PSMA-targeting 18F-radiolabeled pharmaceuticals have developed and successfully used in patients with intermittent- and high-risk prostate cancer or recurrent prostate cancer. The study aims to understand the diagnostic performance of 18F-PSMA-1007 PET/CT in different-stage prostate cancer patients by initiating the first multicenter clinical trial of 18F-PSMA-1007 in Taiwan.


Recruitment information / eligibility

Status Recruiting
Enrollment 230
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender Male
Age group 20 Years to 100 Years
Eligibility Inclusion Criteria 1. The participants are male adults over 20 years old. 2. The participants are suspected prostate cancer patients by a serum PSA value of 4-20 ng/ml or a serum PSA value of < 4ng/ml but noted abnormal lesion by DRE. 3. The participants agree to receive TRUS Bx or mpMRI fusion Bx examination. 4. The participants are the first time to receive a prostatic biopsy. Exclusion Criteria 1. The participants are diagnosed with prostate cancer before this study. 2. The participants have received any related treatment for prostate cancer. 3. The participants have chronic prostatitis. 4. The participants' serum hemoglobin lowers than 10 mg/dl within 1 month. 5. The participants' serum platelet lowers than 15 103/uL within 1 month. 6. The participants' serum prothrombin time (PT) is prolonged longer than 1.2-fold within 1 month. 7. The participants' serum active partial prothrombin time (aPPT) is prolonged longer than 45 seconds within 1 month. 8. The participants have hemorrhagic disease such as Hemophilia, Von Willebrand disease, thrombocytopenia, systemic Lupus Erythematosus, etc. within 6 months. 9. The participants have conditions of poor immunity status such as HIV infection, receiving treatment for other cancer, DM poor control, use of immunomodulator (ex. steroid, etc.) within 6 months. 10. The participants have hypertension poor control that is BP cannot be controlled lower than 140/90mmHg whether or not taking medication within 6 months. 11. The participants have suffered from CVA including infarctions and hemorrhages within 6 months. 12. The participants have suffered from angina including stable and unstable types within 6 months. 13. The participants have suffered from arrythmia poor control within 6 months. 14. The participants have suffered from liver dysfunction such as AST/ALT ratio >2?total bilirubin >1.5 mg/dL within 6 months. 15. The participants are allergic to any radiopharmaceutical or imaging agent. 16. The participants suffered stage IV chronic kidney disease (eGFR<30 mL/min/1.73 m2) within 6 months 17. The participants suffered acute kidney injury within 6 months. 18. The participants are absolute and relative contraindications to MRI examination.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
18F-PSMA-1007
18F-PSMA-1007 PET/CT

Locations

Country Name City State
Taiwan Tungs'Taichung Metro Harbor Hospital Taichung
Taiwan Shin Kong Wu Ho-Su Memorial Hospital Taipei

Sponsors (2)

Lead Sponsor Collaborator
Primo Biotechnology Co., Ltd ABX advanced biochemical compounds GmbH

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic Performance Sensitivity, Specificity, NPV, PPV 7-14 days after PET/CT
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A